Lassa virus diversity and feasibility for universal prophylactic vaccine.

Igor S. Lukashevich, Slobodan Paessler, Juan Carlos de la Torre

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.

Original languageEnglish (US)
Article number134
StatePublished - 2019


  • Lassa fever
  • Lassa virus
  • Vaccine development

ASJC Scopus subject areas

  • General Immunology and Microbiology
  • General Pharmacology, Toxicology and Pharmaceutics
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Lassa virus diversity and feasibility for universal prophylactic vaccine.'. Together they form a unique fingerprint.

Cite this